An interventional study of Personalized and mixed training program in Mitochondrial Myopathies, sponsored by Centre Hospitalier Universitaire de Nice. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Centre Hospitalier Universitaire de Nice · Not applicable, Interventional, and Prevention
Positive effect of physical activity on health arouses a strong interest at international level and is developped within the scope of national programs. Recommandations exist but must be designed for patients with functional limitations of activities.
Patients with mitochondrial diseases have exercice intolerance with an increase of muscular weakness and fatigue after low exercice volume. Theses patients have functional limitations of activities. In order to establish an appropriate training programme, it will be important to define and consider the physical condition. The Society of Mitochondrial Medecine published recommandations for management of theses patients,However, theses recommandations do not allow them to propose a training program of what can be done. For these vulnerable patients, therapists are responsible fo advising a training programm without guidelines to establish its terms and conditions. In addition, some exercices do not appear to have been the subject of complete assessmeents.
Regarding training programs (aerobic training, muscle reinforcement, miwed training), scientific literature shows a significant genetic and clinical variabilities, as well as a lack of data on clinical severity of included patients. In addition, the lack of informations regarding training effects of heteroplamy level limits our comprehension of mechanisms involved in adaptation of mitochondrial pool during training. Therefore, further reserchs on this subject are essential.
It is necessary to offer these patients a follow-up and personalized training program, which are in adequation with daily life. Some publications call on specifics concepts which are not compatible with day-to-day life. The investigators think it will be useful to investigate training effects in order to have practival conclusions, easily reproducible at home by patients with simple and inexpensive equipment. In this context, video consultation could allow the close follow-up of these patients.
The investigators hypothesize that a mixed training (endurance and muscle reinforcement), personalized, at home and followed by video consultation have positive effects on some physical criteria (such as musclar strength, tolerance to effort, functional abilities) without increasing heteroplasmy and creatine phosphokinase levels.
46 studies on the registry are indexed under Mitochondrial Myopathies; 13 are open to participants now.
This study's planned enrollment of 15 is below the median of 26 across 32 interventional studies indexed under Mitochondrial Myopathies.
Browse Mitochondrial Myopathies studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
Patient affected by mitochondrial myopathy, with genetic confirmation of mitochondrial DNA mutation
Procedure: Personalized and mixed training program
Patients perform a personalized and mixed training program (endurance and muscle reinforcement), at home
Change of overall functional capacity of moving during training period from 6 months (S0) to 9 (S12) and 12 (S24) months
The overall functional capacity of moving will be measured by the time to perform the Timed Up and Go test.
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Change of muscular strength of upper and lower limbs during training period from 6 months (S0) to 9 (S12) and 12 (S24) months
Muscular strength of upper (shoulder abduction, elbow and fingers bending) and lower (knee extension) limbs during isometric and maximal muscular contractions will be measured with a quantified muscle testing device. Upper limbs strength will also measured during the developped sitting with dumbbells.
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Change of muscular endurance of upper and lower limbs during training period from 6 months (S0) to 9 (S12) and 12 (S24) months
Muscular endurance of upper (shoulder abduction, elbow and fingers bending) and lower (knee extension) limbs during isometric and maximal muscular contractions, keeped during 30 secondes will be measured by the difference of the force between the beggining and the end of the contraction
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Change of functional abilities in walking during training period from 6 months (S0) to 9 (S12) and 12 (S24) months
Modification of functional abilities in walking will be measured by the maximal distance of walking (in meter) during a 6-minutes walking test
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Change of functional abilities during transferts during training period from 6 months (S0) to 9 (S12) and 12 (S24) months
Modification of functional abilities during transferts will be measured by the maximal number of transferts sitting to standing performed during a 1-minute chair lifts test
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Change of clinical severity of the disease during training period from 6 months (S0) to 9 (S12) and 12 (S24) months
Clinical severity of the disease will be measured with the Newcastle Mitochondrial Disease Scale for Adults (NMDAS) and its 3 first sections. Score ranges from 0 to 145. The higher the score the more severe the disease.
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Change of quality of life during training period from 6 months (S0) to 9 (S12) and 12 (S24) months
Quality of life will be measured with the Quality of Life in Genetic Neuromuscular Disease Questionnaire (QOL-gNMD). The QoL-gNMD is splitted in 3 domains: "Impact of Physical Symptoms" (score from 0 to 19), "Self-perception" (score from 0 to 24) and "Activities and Social Participation" (score from 0 to 27).
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Change of tiredness felt during training period from 6 months (S0) to 9 (S12) and 12 (S24) months
The tiredness felt will be measured with the Fatigue Severity Scale (FSS). The FSS is a unidimensional scale which focuses on the physical aspects of fatigue. It is a self-reported questionnaire developed to measure the impact of disabling fatigue on daily functioning. It covers several areas including physical, social, and cognitive effects. The FSS is a patient-reported outcome composed of 9-items with scores ranging from 1 = "strongly disagree" to 7 = "strongly agree".
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Check effects of a training program on clinical and biological tolerance, by assessing the modification of heteroplasmy level
Heteroplasmy level of mitochondrial DNA from blood and urine samples will be compared between the beginning of the training (6 months, S0), and 9 (S12) and 6 (S24) months after training period.
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Check effects of a training program on clinical and biological tolerance, by regularly assessing the effort-related myalgia
Muscular pain level will be measured with the visual and analog scale for pain before and after each training session. Scorer ranges from 0 to 10, 0 being "no pain" and 10 being "maximum thinkable pain"
Time frame: From 6 months (S0) to 12 months (S24)
Check effects of a training program on clinical and biological tolerance, by assessing the blood creatine phosphokinase levels which is a muscle damage marker
Clinical and biological tolerance will be measured with the blood creatine phosphokinase levels before training and during training period (12 weeks before the begining of training period, at the begining of training period and 2, 4, 8, 12, 16, 20 and 24 weeks after the begining of training period)
Time frame: From 0 (S-24) to 12 months (S24)
Establish a "dose-effect" relationship between the training frequency and effects on clinical parameters (strength, endurance and functionnal abilities such as global moving, walking and during transferts)
Evolution of clinical markers (strength, endurance, global functional abilities in walking and during transferts) will be matched with number of completed training sessions, in order to identify a dose-effect relationship
Time frame: From 0 (S-24) to 12 months (S24)
Check effect of a training program on reported physical condition by assessing the Recent Physical Activity Questionnaire (RPAQ).
RPAQ is a splited in 3 parts: physical activity within and around the house, travel to and from work and your work activity and hobbies. This questionnaire assess: * physical activity level (inactive if score is less than 8.3 Metabolic Equivalent of Task (MET).h/week, moderate if score ranges from 8.3 to 16.7 MET.h/week or high physical activity if score is greater than 16.7 MET.h/week) * sedentary time (settled is score is greater than 7 hours per day or not settled if score is less than or equal to 7 hours per day).
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Check effect of a training program on reported physical condition by assessing the Global Physical Activity Questionnaire (GPAQ).
GPAQ is a splited in 3 parts: activities at work, to move from one place to another and hobbies. For each part, score is ranked according to 3 levels: low, moderate and intense.
Time frame: At 6 (S0), 9 (S12) and 12 (S24) months
Describe the natural history of disease without training on heteroplasmy level
Heteroplasmy level of mitochondrial DNA from blood and urine samples will be assessed at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0).
Time frame: At 0 (S-24) and 6 months (S0)
Describe the natural history of disease without training on blood creatine phosphokinase levels
Blood creatine phosphokinase levels will be assessed at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0).
Time frame: At 0 (S-24) and 6 months (S0)
Describe the natural history of disease without training on muscular strength of upper and lower limbs
Muscular strength of upper (shoulder abduction, elbow and fingers bending) and lower (knee extension) limbs during isometric and maximal muscular contractions will be measured with a quantified muscle testing device at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0). Upper limbs strength will also measured during the developped sitting with dumbbells at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0).
Time frame: At 0 (S-24) and 6 months (S0)
Describe the natural history of disease without training on functional abilities in walking
Modification of functional abilities in walking will be measured by the maximal distance of walking (in meter) during a 6-minutes walking test, at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0).
Time frame: At 0 (S-24) and 6 months (S0)
Describe the natural history of disease without training on functional abilities during transfert
Modification of functional abilities during transferts will be measured by the maximal number of transferts sitting to standing performed during a 1-minute chair lifts test, at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0).
Time frame: At 0 (S-24) and 6 months (S0)
Describe the natural history of disease without training on quality of life
Quality of life will be measured with the Quality of Life in Genetic Neuromuscular Disease Questionnaire (QOL-gNMD) at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0). The QoL-gNMD is splitted in 3 domains: "Impact of Physical Symptoms" (score from 0 to 19), "Self-perception" (score from 0 to 24) and "Activities and Social Participation" (score from 0 to 27).
Time frame: At 0 (S-24) and 6 months (S0)
Describe the natural history of disease without training on tiredness felt
The tiredness felt will be measured with the Fatigue Severity Scale (FSS), at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0). The FSS is a unidimensional scale which focuses on the physical aspects of fatigue. It is a self-reported questionnaire developed to measure the impact of disabling fatigue on daily functioning. It covers several areas including physical, social, and cognitive effects. The FSS is a patient-reported outcome composed of 9-items with scores ranging from 1 = "strongly disagree" to 7 = "strongly agree".
Time frame: At 0 (S-24) and 6 months (S0)
Describe the natural history of disease without training on reported physical condition by assessing the Recent Physical Activity Questionnaire (RPAQ).
RPAQ is a splited in 3 parts: physical activity within and around the house, travel to and from work and your work activity and hobbies. This questionnaire assess, at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0): * physical activity level (inactive if score is less than 8.3 Metabolic Equivalent of Task (MET).h/week, moderate if score ranges from 8.3 to 16.7 MET.h/week or high physical activity if score is greater than 16.7 MET.h/week) * sedentary time (settled is score is greater than 7 hours per day or not settled if score is less than or equal to 7 hours per day).
Time frame: At 0 (S-24) and 6 months (S0)
Describe the natural history of disease without training on reported physical condition by assessing the Global Physical Activity Questionnaire (GPAQ).
GPAQ is a splited in 3 parts: activities at work, to move from one place to another and hobbies. For each part, score is ranked according to 3 levels: low, moderate and intense. GPAC will be assessed at the beginning of observation phase (S-24) and 6 months later, at the beginning of the training (S0).
Time frame: At 0 (S-24) and 6 months (S0)
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice